In the last trading session, 1.72 million Lexeo Therapeutics Inc (NASDAQ:LXEO) shares changed hands as the company’s beta touched 2.45. With the company’s per share price at $1.82 changed hands at $0.03 or 1.68% during last session, the market valuation stood at $60.42M. LXEO’s last price was a discount, traded about -971.43% off its 52-week high of $19.50. The share price had its 52-week low at $1.45, which suggests the last value was 20.33% up since then. When we look at Lexeo Therapeutics Inc’s average trading volume, we note the 10-day average is 1.17 million shares, with the 3-month average coming to 617.65K.
Analysts gave the Lexeo Therapeutics Inc (LXEO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LXEO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Lexeo Therapeutics Inc’s EPS for the current quarter is expected to be -0.77.
Lexeo Therapeutics Inc (NASDAQ:LXEO) trade information
Instantly LXEO was in green as seen at the end of in last trading. With action -41.85%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -72.34%, with the 5-day performance at -41.85% in the red. However, in the 30-day time frame, Lexeo Therapeutics Inc (NASDAQ:LXEO) is -30.53% down. Looking at the short shares, we see there were 2.22 million shares sold at short interest cover period of 4.47 days.
The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 93.5% from its current market value. According to analyst projections, LXEO’s forecast low is 28 with 28 as the target high. To hit the forecast high, the stock’s price needs a -1438.46% plunge from its current level, while the stock would need to soar -1438.46% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -99.98%. The 2025 estimates are for Lexeo Therapeutics Inc earnings to increase by 0.59%, but the outlook for the next 5-year period is at 0.60% per year.
LXEO Dividends
Lexeo Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-23.
Lexeo Therapeutics Inc (NASDAQ:LXEO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.25% of Lexeo Therapeutics Inc shares while 106.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 107.40%. There are 106.06% institutions holding the Lexeo Therapeutics Inc stock share, with EVENTIDE ASSET MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 10.2089% of the shares, roughly 3.37 million LXEO shares worth $54.04 million.
JANUS HENDERSON GROUP PLC holds the second largest percentage of outstanding shares, with 9.5873% or 3.16 million shares worth $50.73 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund . With 1.23 shares estimated at $2.25 million under it, the former controlled 3.72% of total outstanding shares. On the other hand, JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund held about 2.05% of the shares, roughly 682.04 shares worth around $1.24 million.
